Using ST2 in cardiovascular patients: A review

Future Cardiology

Volumn 10, Issue 4, 2014, Pages 525-539

  Daniels, Lori B ^a   Bayes Genis, Antoni ^b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

biomarkers; heart failure; prognosis; risk assessment; ST2

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR; ST2 PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ACUTE HEART FAILURE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; DRESSLER SYNDROME; FUTUROLOGY; HEART FAILURE; HUMAN; MOLECULAR BIOLOGY; PATIENT MONITORING; PATIENT RISK; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; CARDIOVASCULAR DISEASES; METABOLISM;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT;

EID: 84907924762     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.14.36     Document Type: Review

References (55)

1. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5), 721-726 (2003).
2. Bayes-Genis A, Pascual-Figal D, Januzzi JL et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev. Esp. Cardiol. 63(10), 1171-1178 (2010).
3. Ky B, French B, Mccloskey K et al. Highsensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 4(2), 180-187 (2011).
4. Bayes-Genis A, De Antonio M, Galan A et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur. J. Heart Fail. 14(1), 32-38 (2012).
5. Broch K, Ueland T, Nymo SH et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur. J. Heart Fail. 14(3), 268-277 (2012).
6. Lupon J, De Antonio M, Galan A et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin. Proc. 88(3), 234-243 (2013).
7. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi Jr. J.L. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ. Heart Fail. 6(6), 1206-1213 (2013).
8. Felker GM, Fiuzat M, Thompson V et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-Term outcomes. Circ. Heart Fail. 6(6), 1172-1179 (2013).
9. Gaggin HK, Szymonifka J, Bhardwaj A et al. Head-To-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. J. Am. Coll. Cardiol. Hear Fail. 2(1) 65-72 (2014).
10. Boisot S, Beede J, Isakson S et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 14(9), 732-738 (2008).
11. Pascual-Figal DA, Manzano-Fernandez S, Boronat M et al. Soluble ST2, high-sensitivity troponin T-And N-Terminal pro-B-Type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur. J. Heart Fail. 13(7), 718-725 (2011).
12. Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 122(3), 158-166 (2012).
13. Januzzi JL Jr, Peacock WF, Maisel AS et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 50(7), 607-613 (2007).
14. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 54(4), 752-756 (2008).
15. Rehman SU, Mueller T, Januzzi Jr. J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52(18), 1458-1465 (2008).
16. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin. Biochem. 43(9), 714-719 (2010).
17. Socrates T, Defilippi C, Reichlin T et al. Interleukin family member ST2 and mortality in acute dyspnoea. J. Intern. Med. 268(5), 493-500 (2010).
18. Shah KB, Kop WJ, Christenson RH et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin. Chem. 57(6), 874-882 (2011).
19. Breidthardt T, Balmelli C, Twerenbold R et al. Heart failure therapy-induced early ST2 changes may offer long-Term therapy guidance. J. Card. Fail. 19(12), 821-828 (2013).
20. Eggers KM, Armstrong PW, Califf RM et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am. Heart J. 159(5), 788-794 (2010).
21. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction. comparison with Global Registry of Acute Coronary Events Risk Scoring and NTproBNP. Am. Heart J. 161(6), 1163-1170 (2011).
22. Kohli P, Bonaca MP, Kakkar R et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem. 58(1), 257-266 (2012).
23. Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109(18), 2186-2190 (2004).
24. Sabatine MS, Morrow DA, Higgins LJ et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-Terminal prohormone B-Type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117(15), 1936-1944 (2008).
25. Weir RA, Miller AM, Murphy GE et al. Serum soluble ST2: A potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 55(3), 243-250 (2010).
26. Dhillon OS, Narayan HK, Khan SQ et al. Pre-discharge risk stratification in unselected STEMI: Is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?. Int. J. Cardiol. 167(5), 2182-2188 (2012).
27. Daniels LB, Clopton P, Iqbal N et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am. Heart J. 160(4), 721-728 (2010).
28. Wang TJ, Wollert KC, Larson MG et al. Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation 126(13), 1596-1604 (2012).
29. Dieplinger B, Egger M, Koehler W et al. Prognostic value of soluble ST2 in an unselected cohort ofpatients admitted to an intensive care unit-The Linz Intensive Care Unit (LICU) study. Clin. Chim. Acta 413(5-6), 587-593 (2012).
30. Yanagisawa K, Tsukamoto T, Takagi T, Tominaga S. Murine ST2 gene is a member of the primary response gene family induced by growth factors. FEBS Lett. 302(1), 51-53 (1992).
31. Coyle AJ, Lloyd C, Tian J et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190(7), 895-902 (1999).
32. Iwahana H, Yanagisawa K, Ito-Kosaka A et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 264(2), 397-406 (1999).
33. Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106(23), 2961-2966 (2002).
34. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-Associated cytokines. Immunity 23(5), 479-490 (2005).
35. Sanada S, Hakuno D, Higgins LJ et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117(6), 1538-1549 (2007).
36. Mueller T, Zimmermann M, Dieplinger B, Ankersmit HJ, Haltmayer M. Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: The MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. Clin. Chim. Acta 413(19-20), 1493-1494 (2012).
37. Dieplinger B, Januzzi JL Jr, Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-The Presage ST2 assay. Clin. Chim. Acta 409(1-2), 33-40 (2009).
38. Coglianese EE, Larson MG, Vasan RS et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin. Chem. 58(12), 1673-1681 (2012).
39. Dieplinger B, Egger M, Poelz W, Haltmayer M, Mueller T. Long-Term stability of soluble ST2 in frozen plasma samples. Clin. Biochem. 43(13-14), 1169-1170 (2010).
40. Bayes-Genis A, Zamora E, De Antonio M et al. Soluble ST2 serum concentration and renal function in heart failure. J. Card. Fail. 19(11), 768-775 (2013).
41. Dieplinger B, Egger M, Poelz W et al. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clin. Chem. Lab. Med. 49(9), 1515-1518 (2011).
42. Shah RV, Chen-Tournoux AA, Picard MH et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-Term mortality in patients with acute dyspnea. Circ. Heart Fail. 2(4), 311-319 (2009).
43. US FDA. Review memorandum for presage ST2 assay (2014). www.accessdata.fda.gov/cdrh-docs/reviews/ K111452.pdf
44. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. Am. Heart J. 165(6), 995-999 (2013)
45. Anand IS, Rector TS, Kuskowski M et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ. Heart Fail. 7(3), 418-426 (2014).
46. Zilinski JL, Shah RV, Gaggin HK, Gantzer ML, Wang TJ, Januzzi Jr. J.L. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit. Care 16(4), R135 (2012).
47. Bajwa EK, Volk JA, Christiani DC et al. Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome. Crit. Care Med. 41(11), 2521-2531 (2013).
48. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62(16), e147-e239 (2013).
49. Januzzi JL Jr, Rehman S, Mueller T, Van Kimmenade RR, Lloyd-Jones DM. Importance of biomarkers for long-Term mortality prediction in acutely dyspneic patients. Clin. Chem. 56(12), 1814-1821 (2010).
50. Rehman SU, Januzzi Jr. J.L. Natriuretic peptide testing in clinical medicine. Cardiol. Rev. 16(5), 240-249 (2008).
51. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54(23), 2174-2179 (2009).
52. Ky B, French B, Levy WC et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ. Heart Fail. 5(2), 183-190 (2012).
53. Bayés-Genís A, Lupón J. Calculations. BCN Bio-HF Calculator (2013). www.bcnbiohfcalculator.org
54. Lupon J, De Antonio M, Vila J et al. Development of a novel heart failure risk tool: The Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS ONE 9(1), e85466 (2014).
55. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351(6), 543-551 (2004).